对印度南部医护人员在服用COVID-19预防剂量后的不良事件和突破性感染进行哨点监测

Merrin Mathew, J. Sebastian, C. Basavaraja, Devayani Josh, Deleena Varughese, Sidharth Soman, Madhu Sreeja Mahalekshmi
{"title":"对印度南部医护人员在服用COVID-19预防剂量后的不良事件和突破性感染进行哨点监测","authors":"Merrin Mathew, J. Sebastian, C. Basavaraja, Devayani Josh, Deleena Varughese, Sidharth Soman, Madhu Sreeja Mahalekshmi","doi":"10.24294/ti.v7.i2.2216","DOIUrl":null,"url":null,"abstract":"Background: Adverse events following immunization (AEFI) is defined as any untoward medical occurrence which follows immunization and which does not necessarily have a causal relationship with the usage of the vaccine. Break-through infections are referred to as antigen or SARS-CoV-2 RNA positivity of respiratory specimens more than 14 days after receiving all recommended doses. Aim: The study was conducted to identify adverse events and break-through infections following the precautionary dose of the COVID-19 vaccine among healthcare workers. Methodology: The study was designed as a cohort event monitoring; all healthcare professionals who received COVID-19 precautionary dose from the study site were included in the study. The study population was actively followed for any adverse event following immunization (AEFI) through telephonic contact (within 30 days of post-vaccination). Reported adverse events were carefully scrutinized and evaluated by the AEFI investigation team of the study site. Results: Out of 1232 vaccine beneficiaries, a total of 359 (29.14%) individuals were reported with 385 AEFIs. Of which 138 (38.44%) individuals were laboratory-confirmed (RTPCR positive) breakthrough cases. Less severity and low morbidity were observed among all the breakthrough cases. According to the WHO’s new causality assessment algorithm, 183 (47.53%) events were vaccine product-related and 202 (52.46%) were co-incidental events. Conclusion: There was a prevailing outbreak of COVID-19 infection in the study site, which resulted in many breakthrough infections soon after immunization. Initially, all breakthrough infections were misleading as vaccine-related events, where this study helped to break the concerns among the study population.","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A sentinel surveillance of adverse events and breakthrough infections following COVID-19 precautionary dose among south Indian healthcare workers\",\"authors\":\"Merrin Mathew, J. Sebastian, C. Basavaraja, Devayani Josh, Deleena Varughese, Sidharth Soman, Madhu Sreeja Mahalekshmi\",\"doi\":\"10.24294/ti.v7.i2.2216\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Adverse events following immunization (AEFI) is defined as any untoward medical occurrence which follows immunization and which does not necessarily have a causal relationship with the usage of the vaccine. Break-through infections are referred to as antigen or SARS-CoV-2 RNA positivity of respiratory specimens more than 14 days after receiving all recommended doses. Aim: The study was conducted to identify adverse events and break-through infections following the precautionary dose of the COVID-19 vaccine among healthcare workers. Methodology: The study was designed as a cohort event monitoring; all healthcare professionals who received COVID-19 precautionary dose from the study site were included in the study. The study population was actively followed for any adverse event following immunization (AEFI) through telephonic contact (within 30 days of post-vaccination). Reported adverse events were carefully scrutinized and evaluated by the AEFI investigation team of the study site. Results: Out of 1232 vaccine beneficiaries, a total of 359 (29.14%) individuals were reported with 385 AEFIs. Of which 138 (38.44%) individuals were laboratory-confirmed (RTPCR positive) breakthrough cases. Less severity and low morbidity were observed among all the breakthrough cases. According to the WHO’s new causality assessment algorithm, 183 (47.53%) events were vaccine product-related and 202 (52.46%) were co-incidental events. Conclusion: There was a prevailing outbreak of COVID-19 infection in the study site, which resulted in many breakthrough infections soon after immunization. Initially, all breakthrough infections were misleading as vaccine-related events, where this study helped to break the concerns among the study population.\",\"PeriodicalId\":401129,\"journal\":{\"name\":\"Trends in Immunotherapy\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in Immunotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24294/ti.v7.i2.2216\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Immunotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24294/ti.v7.i2.2216","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:免疫不良事件(AEFI)被定义为免疫接种后发生的任何不良医学事件,与疫苗使用不一定有因果关系。突破性感染是指在接受所有推荐剂量后超过14天,呼吸道标本出现抗原或SARS-CoV-2 RNA阳性。目的:本研究旨在确定医护人员接种预防剂量COVID-19疫苗后的不良事件和突破性感染。方法:本研究设计为队列事件监测;所有从研究地点接受COVID-19预防剂量的医疗保健专业人员都被纳入研究。通过电话联系(接种疫苗后30天内)积极跟踪研究人群免疫后的任何不良事件(AEFI)。报告的不良事件由研究地点的AEFI调查小组仔细审查和评估。结果:在1232名疫苗受益人中,共有359人(29.14%)报告了385例aefi。其中实验室确诊(RTPCR阳性)突破病例138例(38.44%)。所有突破病例的严重程度和发病率均较低。根据WHO新的因果关系评估算法,183例(47.53%)事件与疫苗产品相关,202例(52.46%)事件为偶发事件。结论:研究地点存在流行的COVID-19感染疫情,在免疫后不久出现了多例突破性感染。最初,所有突破性感染都被误认为是与疫苗有关的事件,而这项研究有助于打破研究人群中的担忧。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A sentinel surveillance of adverse events and breakthrough infections following COVID-19 precautionary dose among south Indian healthcare workers
Background: Adverse events following immunization (AEFI) is defined as any untoward medical occurrence which follows immunization and which does not necessarily have a causal relationship with the usage of the vaccine. Break-through infections are referred to as antigen or SARS-CoV-2 RNA positivity of respiratory specimens more than 14 days after receiving all recommended doses. Aim: The study was conducted to identify adverse events and break-through infections following the precautionary dose of the COVID-19 vaccine among healthcare workers. Methodology: The study was designed as a cohort event monitoring; all healthcare professionals who received COVID-19 precautionary dose from the study site were included in the study. The study population was actively followed for any adverse event following immunization (AEFI) through telephonic contact (within 30 days of post-vaccination). Reported adverse events were carefully scrutinized and evaluated by the AEFI investigation team of the study site. Results: Out of 1232 vaccine beneficiaries, a total of 359 (29.14%) individuals were reported with 385 AEFIs. Of which 138 (38.44%) individuals were laboratory-confirmed (RTPCR positive) breakthrough cases. Less severity and low morbidity were observed among all the breakthrough cases. According to the WHO’s new causality assessment algorithm, 183 (47.53%) events were vaccine product-related and 202 (52.46%) were co-incidental events. Conclusion: There was a prevailing outbreak of COVID-19 infection in the study site, which resulted in many breakthrough infections soon after immunization. Initially, all breakthrough infections were misleading as vaccine-related events, where this study helped to break the concerns among the study population.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信